AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Gregorio A. Cortes-Maisonet

Gregorio A. Cortes-Maisonet

GCM Medical Group - San Juan / Puerto Rico
Others
AD Scientific Index ID: 4969468
Grupo Médico GCM
person_outline Gregorio A. Cortes-Maisonet's MOST POPULAR ARTICLES
1-) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial The Lancet 394 (10193), 121-130, 2019
2-) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial The Lancet 398 (10313), 1811-1824, 2021
3-) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial The Lancet 394 (10193), 131-138, 2019
4-) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet 402 (10402), 613-626, 2023
5-) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind, placebo‐controlled … Arthritis & rheumatology 71 (4), 599-611, 2019